Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Second Year Things > Pharmaceutics Final > Flashcards

Pharmaceutics Final Flashcards

1
Q

Diagnostic Tests

A
  • Needed to evaluate health and
    1. Diagnose disease in a patient
    2. Decide on the most appropriate treatment and,
    3. Monitor the effects of treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sensitivity

A

The fraction of patients who have the disease that is correctly predicted by the test

Sensitivity = TP/(TP + FN)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Specificity

A

The fraction of patients who do not have the disease that is correctly predicted by the test

Specificity = TN/(TN + FP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

True Positive

A

Individuals who have the disease that are correctly classified by the test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

False Positive

A

Individuals who do not have the disease that are incorrectly classified by the test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

True Negative

A

Individuals who do not have the disease that are correctly classified by the test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

False Negative

A

Individuals who have the disease that are incorrectly classified by the test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dichotomous Test

A
  • One of two options

- Ex: Positive vs. Negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Continuous Test

A

Range of values with a threshold set for a reference population vs. disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Continuous Test: Prostate Specific Antigen

A

-Depending on where we set the threshold, this will determine the number of TP, FP, TN, and FN and therefore the sensitivity and specificity of the test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Receiver Operating Characteristic Curves

A

X: 100-Specificity (false positive rate)
Y: Sensitivity (true positive rate)

Provides optimal region for high sensitivity and specificity in order to choose a threshold for continuous data

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Predictive Values

A

Positive: PPV = TP/(TP + FP)
-Likelihood that a positive test result will indicate disease

Negative: NPV = TN (TN + FN)
-Likelihood that a negative test result will indicate no disease

These numbers are affected by prevalence of disease

  • High prevalence increases PPV, decrease NPV
  • Low prevalence decreases PPV, increases NPV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Acute Myocardial Infarction

A

-Changes in cardiac biomarkers (especially troponin) above the 99th percentile of the upper reference limit, together with evidence of ischemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Evidence of Ischemia

A
  1. Ischemic symptoms
  2. ECG changes associated with ischemia
  3. Pathologic Q-waves on ECG
  4. Imaging tests showing new loss of viable myocardium or new regional wall motion abnormality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cardiac Troponin Complex

A
  • Cardiac Troponin-I (cTnI) is the inhibitory form
  • Troponin-T (cTnT) is the tropomyosin-binding form
  • Both are found in skeletal muscle
  • AMI causes release of both into the plasma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Principle of Immunoassay (e.g., ELISA)

A
  • Monoclonal antibodies (Ab1) specific for the analyte (Ag) are used to bind the analyte in a plasma or serum sample and extract it for measurement - known as primary antibodies
  • Secondary antibodies (Ab2) that are usually polyclonal and carry a label are used to measure the amount of immune complexes formed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Sandwich or Direct Immunoassay

A
  • 96 well plates made of 96 tiny plates
  • Primary antibody is stuck to the bottom of the plate
  • Add plasma and incubate
  • Wash to make sure all that is left is primary antibodies stuck to protein of interest
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Abbott AxSYM Assay for cTnI

A
  1. Anti-cTnI (mouse monoclonal antibody) coated onto microparticle
  2. cTnI in serum sticks to antibody
  3. Anti-TnI (Goat)-AlkPhos (secondary antibody) sticks to certain part of cTnI separate from the primary antibody to form 4-methylumbelliferyl phosphate, which fluoresces at 365 nm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Limitations of cTnI Assays

A
  • No primary cTnI reference standard to calibrate different assays - each commercial assay uses their own reference material for calibration
  • Definition of “normal” reference limits is unique for each commercial assay and depends on the sensitivity (e.g., high sensitivity assays have different limits)
  • Results with one assay are not easily comparable to those using another assay - best to follow changes in cTnI for an individual patient over time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Sensitivity and Specificity of cTnI Assays

A
  • Sensitivity 91.8%
  • Specificity 92.4%
  • Sensitivity increases from 65% to >90% as time from presentation exceeds 5 hours, but specificity remains >90% at all times
  • Sensitivity increases because the longer you wait after someone has MI, the more troponin you have in the body
  • Specificity stays the same because the longer you wait, someone who does not have MI, still does not have MI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Kinetics of cTnI Elevation following MI

A
  • Reperfusion of the myocardium by angioplasty or thrombolytic agents causes a more rapid decline in cTnI levels but higher initial values
  • cTnI replaced creatinine kinase muscle and brain subunits (CK-MB)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Acute cTnI Elevation in Absence of MI

A
  1. Myocardial trauma (e.g., ICD firings, biopsy, cardioversion)
  2. CHF
  3. Myocardial surgery
  4. Renal failure
  5. Critically ill patients
  6. Drug toxicity (e.g., CO2 poisoning)
  7. Myocarditis
  8. Sepsis (due to TNF release)
  9. Other conditions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hypothyroidism

A
  • Deficiency of TH secretion (T3 and T4)
  • Occurs in 2-15% of the population
  • Primary due to thyroid gland failure
  • Central due to pituitary gland dysfunction (low TSH)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Hyperthyroidism

A
  • Elevated TH secretion (T3 or T4)
  • Grave’s disease occurs in 0.4% of population
  • Primary due to overactive thyroid gland
  • Central due to pituitary/hypothalamus dysfunction (high TSH)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

TSH Assays

A
  • TSH is a 28-30 kDa dimeric glycoprotein consisting of an alpha and beta subunit
  • Most assays are “sandwich” type direct immunoassays
  • Assays calibrated using TSH reference preparation (WHO 2nd IRP 80/558)
  • Results expressed as milli-international units of biological activity per L of serum (mIU/L) based on a comparison to a bioassay for TSH
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Biocheck TSH Enzyme Assay

A
  1. Immobilized anti-TSH monoclonal antibody incubated in serum
  2. Wells in MicroELISA plate and washed
  3. Add goat anti-TSH-horseradish peroxidase (HRP)
  4. Measure absorbance at 450 nm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Linearity of TSH Measurement

A
  • Limitation of ELISA is non-linearity because of saturation

- Non-linearity due to insufficient primary anti-TSH antibody coated onto microELISA plate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Competition T4 Immunoassay

A
  1. T4 plasma competes with labeled T4 (*T4) for binding to a monoclonal antibody (Ab1).
  2. *T4-Ab1 complex is separated from any free *T4 and measured
  3. Signal (chemoluminescent substrate) obtained is plotted vs. concentration of unlabeled T4 for a series of known concentrations of T4
  4. Unknown T4 concentration in the plasma is determined measuring its signal and referring to standard curve

-RLU is measured unknown amount, which corresponds to the real T4 concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Liver Diseases

A
  • Acute hepatitis
  • Cholestasis (blockage of common bile duct)
  • Chronic hepatitis
  • Cirrhosis
  • Hepatocellular carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Algorithm for Assessing Liver Dysfunction

A

Abnormal Liver Function Test –> AST/ALT >3xURL, ALP Hepatocellular disease –> normal albumin = acute hepatitis; decreased = chronic hepatitis

Abnormal Liver Function Test –> AST/ALT 2xURL –> Cholestatic disease –> normal albumin = acute; decreased = chronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Aspartate Aminotransferase

A

Aspartate + 2-oxoglutarate –AST–> oxaloacetate + glutamate

  • Produced in liver, but other places too
  • Less specific than ALT

ASSAY: Coupled Enzyme Assay
Oxaloacetate –MD–> Malate converts NADH to NAD+
Measure decrease in abs at 340 nm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Alanine Aminotransferase

A

Alanine + 2-oxoglutarate –ALT–> pyruvate + glutamate

  • Produced in the liver primarily
  • More specific than AST

ASSAY: Coupled Enzyme Assay
Pyruvate –LD–> Lactate converts NADH to NAD+
Measure decrease in abs at 340 nm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Coupled Enzyme Assay

A
  • Product of one reaction becomes the substrate of another, which can be measured
  • Usually measuring NADH to NAD+ by measuring the decrease in absorbance at 340 nm (NADH)
  • Michaelis-Menten allows us to know that as long as the substrate is in excess, the rate of creation is constant and proportional to the amount of enzyme present
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Alkaline Phosphate

A
  • Several isoforms including bone, intestinal, liver and kidney ALP
  • Most originates in the liver and bone-
  • Increased serum ALP associated with liver dysfunction or bone osteoblastic activity
  • There is increased synthesis of ALP in response to cholestatic disease

ASSAY: Colourmetric Assay
-Add a colorless compound and ALP turns it into a yellow compound, which can be measured at 405 nm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Serum Albumin Assays

A

Colourmetric Assay

-Add bromocresol green or purple and measure absorbance at 610-620 nm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

RI for Hepatic Dysfunction

A
  • AST/ALT increase 10-40 fold
  • ALT increases 10-12 fold
  • Albumin can remain normal or decrease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Kidney Function Tests

A
  • Proteinuria
  • Serum Creatinine
  • Creatinine Clearance
  • Urine: Glucose, uric acid, hemoglobin, leukocytes, pH and specific gravity
  • BUM (serum)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Proteinuria

A
  • Passage of serum proteins into the urine by the kidney glomeruli
  • Proteins eliminated in the urine should be
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Serum Creatinine

A

Creatinine is synthesized in the kidneys, liver and pancreas and transported to muscle and brain where it is phosphorylated

  • A small proportion of phosphocreatine is converted to creatinine and excreted by the kidneys
  • Serum creatinine is a marker for renal function

ASSAY:

  1. Jaffe Reaction
  2. Coupled Enzyme Reaction involving creatininase that generates hydrogen peroxide,m which converts a substrate into a coloured product that can be measured
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Jaffe Reaction

A

SCr Assay

Picric Acid + Creatinine –OH–> RED-ORANGE COMPLEX (picrate-creatinine complex)
-Measure absorbance at 490-500 nm

Technical Problems

  1. Not specific for creatinine
  2. Small interferences from protein, glucose, ascorbic acid, ketones, cephalosporins, bilirubin and others
  3. Some assays compensate by subtracting a fixed concentration from the SCr value
  4. Some assays overestimate SCr by 20%
  5. Enzyme-based assays are more specific but still have some interferences (e.g., bilirubin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Creatinine Clearance and GFR

A

-Clearance: Volume of plasma that is completely cleared of a substance per unit of time
-Creatinine is cleared mainly by glomerular filtration, thus its clearance is an estimate of GFR
+Tubular secretion can cause errors (7-10%)
-Creatinine Clearance measurements require timed urine collections to measure excretion rate of creatinine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Equations for Converting SCr into GFR

A
  1. Cockcroft and Gault Equation
    a. Age
    b. Weight
    c. Sex
    d. SCr
  2. Modification in Diet in Renal Disease (MDRD)
    a. Age
    b. SCr
    c. Sex
    d. Black
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

RI for Renal Dysfunction

A
  • Urinary protein and SCr increase

- GFR decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Criteria for TDM

A
  1. Narrow TI
  2. Correlation between plasma/serum concentration and efficacy or toxicity
  3. Variability in inter-individual PK
    - Liver or kidney dysfunction may effect elimination
    - Non-linear PK
  4. Absence of a biomarker of therapeutic response
  5. Potential drug interactions that could effect plasma/serum concentrations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Analytic Methods for TDM

A
  1. Immunoassays
  2. GC-MS, LC-MS
  3. HPLC-UV
  4. Ion-selective Electrodes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Immunoassays

A
  1. Radioimmunoassay
  2. Enzyme-Linked Immunosorbent Assay (ELISA)
  3. Enzyme-Multiplied Immunoassay (EMIT)
  4. Cloned-Enzyme Donor Immunoassay (CEDIA)
  5. Chemiluminescence Immunoassay
  • Most common
  • Easily automated
  • Versatile
  • Relative specific for drug
47
Q

Radioimmunoassay

A
  1. Incubate antibody-bound radiolabeled drug affixed to plate + drug in plasma/serum
  2. Drug competes with radiolabeled drug
  3. Measure antibody-bound radiolabeled drug to determine amount of antibody-bound drug there is indirectly

Heterogenous because you have to wash away free radiolabeled drug

Ex. Digoxin

48
Q

Digoxin RIA

A

Interfering substances

  1. Digoxin-like immunoreactive factor (DLIF)
    - Present in pregnant women and neonates
    - Affinity to primary antibody is much lower than actual drug, but can still interfere
    - Different assays have more specificity
  2. Other substances with steroid structure
49
Q

EMIT Assay

A

Enzyme-Multiplied Immunoassay

  1. Antibody-bound drug-enzyme conjugate (inactive) + drug in plasma/serum
  2. Real drug competes with enzyme-bound
  3. Free drug-enzyme conjugate will react with substrate and be active for measurement
  4. Measure colour

Homogeneous because the bound drug-enzye conjugate is inactive and so no separation is needed

Ex. Gentamicin

50
Q

EMIT 2000 Gentamicin Assay

A

EMIT Beckman-Coulter

Drug: Gentamicin
Enzyme: G6PD
Substrate: Glucose

Conversion of glucose to gluconolactone by G6PD results in production of NADPH, which is measured at 340 nm

51
Q

Chemilluminescence

A

Acridinium esters undergo a chemical reaction when exposed to hydrogen peroxide that produces light that can be measured

Ex. Phenytoin

52
Q

Abbott Architect Phenytoin CIA

A
  1. Phenytoin-Acridinium conjugate bound to antibody on micro particle + phenytoin in plasma/serum
  2. Measure proportion of bound forms indirectly by measuring chemiluminescence for phenytoin-acridinium conjugate bound to micro particle

Heterogeneous immunoassay

53
Q

Clinical Toxicology

A
  1. ALCOHOL
  2. SALICYLATES
  3. ACETAMINOPHEN
  4. Amphetamines
  5. Cannabinoids
  6. Cocaine
  7. Opiates
  8. PCP
  9. Sedative hypnotics
  10. Carbon monoxide
54
Q

Clinical Toxicology: Patient Considerations

A

Primary survey of patient condition

  • Patient history
  • Initial physical exam
  • Ancillary tests

Secondary survey of patient condition

  • Complete and more detailed physical exam
  • Exam of items brought with patient
  • More specific lab tests
55
Q

Clinical Toxicology: Point of Care Drug Screen

A
  • Drug in urine competes for binding with fluorescently labeled drug to channel in cartridge
  • Fluoresence measured in POC meter
  • Only tells presence of drug over threshold, not actual concentration

Limitations

  1. Drug may be present in lower than threshold conc
  2. Does not indicate if level of drug is toxic, only that drug is present in urine
  3. Does not provide concentration of drug
56
Q

Clinical Toxicology: Ethanol Assay

A
  1. Enzymatic Assay
    Ethanol + NAD+ –ADH–> Acetaldehyde + NADH (measured at 340 nm)
  2. Osmolar Gap
    - Measure freezing point depression of plasma sample in osmometer
    - Osmolar gap = measured osmolality - calculated osmolality (which is about 275-295 mOsm/kg for plasma)
    - Serum osmolality increases by 10 mOsm/kg for each 0.06 g/100 mL ethanol

Note: Other alcohols can be measured using GC

57
Q

Clinical Toxicology: Acetaminophen Assay

A

Enzymatic

Acet –acidamide amidohydrogenase–> p-aminophenol –o-cresol; NH3/Cu2+–> BLUE COLOUR

58
Q

Clinical Toxicology: Acetaminophen Rumack-Mathew Nomogram

A
  • Hepatic toxicity of acetaminophen due to reactive metabolite (NAPQI)
  • Probability of hepatic toxicity depends on the time since ingestion and the plasma concentration of acetaminophen defined by nomogram
  • Y-axis: Acet plasma conc; X-axis: Time since ingestion
  • There is a 4 hour delay between ingestion and assessment of clinical significance

NOTE: Antidote is acetylcysteine

59
Q

Clinical Toxicology: Salicylate Assay

A
  1. Trinder Reaction (Colourmetric)
    Aspirin + Fe3+ –> VIOLET (measure at 540 nm)
  2. Enzymatic Assay
    Salicylate + NADH + H+ –salicylate hydroxylase–> Catechol + NAD+
    Measure decrease in abs at 340 nm
60
Q

Biomaker

A

Characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic response to a therapeutic intervention

61
Q

Role of Biomarkers in Cancer

A
  1. Screening for early detection
  2. Aiding in diagnosis of cancer
  3. Predicting survival from cancer
  4. Predicting therapeutic response
  5. Tumour staging
  6. Detecting recurrence of cancer
  7. Monitoring the effectiveness of treatment
62
Q

Examples of Biomarkers in Cancer

A
  1. CEA –> colon –> IA, IHC
  2. PSA –> prostate –> IA
  3. CA125 –> ovarian –> IA
  4. CA19-9 –> pancreatic –> IA
  5. HER2 –> breast, gastric –> IHC, FISH
  6. EGFR –> colon, lung –> IHC
  7. ER, PgR –> breast –> IHC
  8. Kras –> lung –> RT-PCR
  9. Bcr-Abl –> CML –> RT-PCR
  10. CD20 –> B-cell lymphoma –> IHC, FC
63
Q

Carcinoembryonic Antigen

A

CEA - colon cancer - IA, IHC

  • Cell surface glycoprotein adhesion molecule
  • Elevated in the serum in COLORECTAL, lung, gastric, breast and pancreatic cancer but some false positives and negatives
  • Serum CEA decreases with successful treatment of colorectal cancer and rises with recurrence

USED for detection of Recurrent COLORECTAL CANCER
-At >10 U/L, sensitivity is 50%, specificity is 99%; PPV is 74%, NPV is 92%

64
Q

Prostate Specific Antigen

A

PSA - prostate cancer - IA

  • Glycoprotein protease found in prostate gland
  • Elevated in prostate cancer
  • Used as a screening tool for prostate cancer, followed up by biopsy for diagnosis
65
Q

CA125

A

ovarian cancer - IA

  • Glycoprotein expressed mainly by ovarian cancer but also endometrial, pancreatic, lung, breast and colorectal cancer
  • Increased in serum as disease progresses from Stage I
  • At >35 U/L, sensitivity is 95% and specificity is 82%
  • Detection of recurrent or residual disease after treatment but NOT for screening except in high risk women
66
Q

CA19-9

A

pancreatic - IA

  • Glycolipid secreted by normal pancreas and biliary duct cells
  • Elevated in pancreatic cancer, gastric, hepatobiliary and other cancers
  • At >37 U/mL, sensitivity is 69-93%, specificity is 76-99%
67
Q

HER2

A
  • Overexpressed in 20-25% of breast cancers
  • Target for trastuzumab (Herceptin)
  • Patients selected for treatment by IHC staining for HER2 or by FISH
68
Q

Immunohistochemistry (for HER2)

A
  1. Add primary antibody that recognizes HER2 and wash
  2. Add secondary antibody conjugated to an enzyme (HRP)
  3. Add DAB substrate and hydrogen peroxide - forms a colour (brown) by reacting with enzyme on the tissue section
69
Q

Fluorescence in Situ Hybridization (for HER2)

A
  1. Incubate with fluorescently labeled oligonucleotides that bind to copies of HER2 gene
  2. Examine cells for fluorescence - pink is HER2, green is control
70
Q

Estrogen and Progesterone Receptors

A
  • Both are measured in breast cancer by IHC staining of a tumour biopsy
  • Positive staining of more than 1% of tumour cell nuclei is considered ER-positive, but response to anti-estrogen therapy is most common with positive staining of over 20% of cells
  • Can use tamoxifen and aromatase inhibitors (e.g., Letrozole) to treat ER positive breast cancer
71
Q

Mammaprint

A
  • Probes 70 genes to separate early stage node-negative breast cancer patients into low or high risk for recurrence
  • Patients at high risk may need chemo
72
Q

OncoType DX

A
  • Probes 21 genes to derive a recurrence score for ER-positive early stage breast cancer
  • Aids in decision-making about treatment
  • Performed by Reverse-Transcriptase PCR
73
Q

CD20

A

Non-Hodgkin’s Lymphoma

  • Cell surface phosphoprotein expressed on normal B cells and on non-Hodgkin’s B-cell lymphoma
  • Target for monoclonal antibody, rituximab (Rituxan)

Flow Cytometry analysis of CD20 expression on B-cells

  • Based on the binding of fluorescently-labeled antibodies to cells and their sorting by fluorescence intensity
  • More than 90% of B-cell lymphomas express CD20
74
Q

Bcr-Abl

A

Translocation in CML

  • Translocation of Abl gene from chromosome 9 to 22 in 90% of cases
  • Forms Bcr-Abl fusion gene that leads to protein that is constitutively active (tyrosine kinase) and responsible for proliferation of CML
  • Imatinib (Gleevec) is a tyrosine kinase inhibitor which competes with ATP for the phosphorylation sites on Bcr-Abl protein
  • Can use real time RT-PCR to measure Bcr-Abl transcripts using threshold value
75
Q

K-ras

A

Biomarker for EGFR-Targeted Therapies

  • Mutation in K-ras predicts resistance for EGFR-targeted therapies (e.g., cetuximab or panitumumab)
  • Can be measured using real time PCR
  • Mutation leads to permanently active EGFR signaling and continue proliferation; treatment works upstream of this and so is useless when the mutation is present
76
Q

Point-of-Care Tests

A
  • Lab testing performed at or near the site where clinical care is delivered
  • May be performed by the patient or by a health care professional - decreases time required for a lab result allowing adjustments in patient care to improve outcomes
  • Many different analytes
77
Q

POCT Pro and Con

A

PRO

  • Portable and convenient
  • Rapid results
  • Small sample volumes
  • No sample processing and decreased administrative documentation
  • Specific identification of marker
  • Ease of use
  • Improved patient management

CON

  • Quality is operator-dependent
  • Operators are clinically-focused and not lab trained
  • Overutilization of testing and inappropriate use
  • Difficult to assure regulatory compliance
  • Sometimes not quantitative
  • May increase costs
  • Increased risk of error
78
Q

Glucose Monitoring in Diabetes

A
  • Target glucose concentration: 90-130 mg/dL (5.0-7.2 mmol/L)
  • Prolonged hyperglycemia increases the risk for diabetic retinopathy and cardiac disease as well as tissue infections (sometimes leading to amputations)
  • Hypoglycemia is also a serious risk that can lead to coma and death
  • Blood glucose monitoring is commonly employed in insulin-dependent Type I and II diabetics to maintain levels within acceptable range by insulin administration
79
Q

Blood Glucose Measurement - GOx and GDH

A

SEE PICTURES

80
Q

Blood Glucose Measurement - Mediators

A
  • Mediators receive and transfer electrons from GOX or GDH driving the reaction and producing the electrons we can measure once glucose is converted
  • Ferricyanide, ferrocene, PQQ
81
Q

Glucose Monitors

A
  • Electrochemical Cell
  • Oxidation occurs at the anode, measuring actual reaction where the mediator is producing electrons upon glucose conversion
  • Reduction occurs at the cathode, measuring reaction that is constantly occurring in the environment as a control
82
Q

Glucose Test Strips

A
  • Strip contains semi-permeable membrane to separate “plasma-like” liquid from cells as well as all the reagents (e.g., mediators and enzymes) needed to initiate the electrochemical reaction
  • Electrodes are printed onto the strip using an ink jet printer that dispenses carbon, gold or palladium for working electrode and Ag/AgCl for counter/reference electrode
83
Q

Test Strip Calibration

A

-Coding is the slope and intercept of a plot of current (uAmps) for an individual lot of strips vs. glucose concentration measured by a reference method
-This differs for each lot of strips and previously needed to be entered into the glucometer
-Reference method uses hexokinase to measure glucose
+SEE PICTURES
+Uses hexokinase as the enzyme and converts glucose + ATP into gluc-6-phosphate –> converted to 6-phsophogluconate with the conversion of NADPH to NADP+ (at 340 nm)

84
Q

Commercial Glucometers

A
  • One Touch Ultra - GOx, ferricyanide
  • Ascensia Contour - GDH, ferricyanide
  • Accucheck Aviva - GDH, PQQ
85
Q

ISO 15197 Standard - Health Canada

A

In 2010, they determined that a lot of meters were not compliant with ISO 15197 standard

86
Q

Clarke Error Grid

A
  • Used to figure out if glucose meters are good
  • The dots are glucose measurements and the Y-axis is the concentration according to the meter, X is glucose concentration according to lab tests (“real”)
  • We want a perfectly diagonal line for perfect meter

ZONES

  • A: Clinically accurate
  • B: Benign over/under-estimation; still compliant
  • C: Unacceptable over/under-estimation
  • D: Unacceptable failure to detect; meter telling you that you have high levels when you don’t or low when they are high
  • E: Unacceptable errors
87
Q

Icodextrin in Peritoneal Dialysis

A

-Metabolized into glucose and maltose
-Cannot be differentiated from glucose by GDH, better to use GOx
-Causes falsely-elevated glucose readings
-US FDA Warning
+13 deaths from 1997-2009 in patients; 10 who were receiving peritoneal dialysis with icodextrin solutions and 3 received other maltose containing drugs
+Falsely-elevated glucose readings specific for glucometers using GDH-PQQ test strips

88
Q

Other Drug Interferences of Glucose Monitoring

A

Drug –> Interfering Concentration (mg/dL)

  1. Acetaminophen –> >20
  2. Salicylic acid –> >50
  3. Tetracycline –> >4
  4. Dopamine –> >13
  5. Ephedrine –> >10
  6. Ibuprofen –> >40
  7. L-DOPA –> >5
  8. Methyl-DOPA –> >2.5
  9. Tolazamide –> >100
  10. Ascorbic acid –> >3
89
Q

Sources of Error in Glucose Measurement

A
  1. Hematocrit - should be 25-55%
    - Oxygen in RBCs may compete with mediator for e-
    - High Hct limits diffusion of sample and reactants
    - Inverse relationship between Hct and strip response
  2. Skin Contamination
    - Glucose on fingertips can cause false high readings (e.g., grapes)
    - Always wash hands before collecting blood
  3. Miscoding
    - Correct coding must be entered for calibration of the glucometer and accurate glucose reading
90
Q

First Response Pregnancy Test

A
  1. Remove overcap and expose the absorbent tip to urine. Wait for 1 minute.
  2. Observe for one pink line (not pregnant) or two pink lines (pregnant).
  3. Measures increased human chorionic gonadotropin (hCG > 25-50 IU/L)
91
Q

Immunochromatography POCT

A
  • Sample migrates along the strip where it binds to gold particles linked to antibody conjugates and then later to reagents that form a colour if the protein is present (test line)
  • The control line has antibodies that recognize the gold particles to ensure the test is operating correctly
92
Q

Cardiac Troponin-T POCT

A
  • Immunochromatography
  • Blood travels through the test and picks up cardiac troponin to indicate heart disease
  1. Gold anti-TnT
  2. Biotin anti-gold (TnT) complex
  3. Streptavidin-Label (test)
  4. TnT-Label (control)
93
Q

Streptococcus Group A POCT

A
  • Immunochromatography test using throat swab detects Strep A carbohydrate antigen (95% specific in 5 minutes)
  • Strep A causes rheumatic fever and peritonsillar abscesses
  • Throat swab blood agar plate culture is reference standard
94
Q

Pneumococcal Urinary Antigen POCT

A
  • Immunochromatography detects C-polysaccharide common to all pneumococcal serotypes (92% sensitive, 100% specific in 15 minutes)
  • CAP most frequently caused by S. pneumo
95
Q

Lipoproteins

A
  • Molecules made up of lipids and proteins
  • Proteins act as emulsifying agents so that the lipid can travel through the body
  • Separated by density using ultracentrifugation into chylomicrons, VLDL, LDL and HDL
  • LDL is 62% cholesterol, HDL is 19%
  • LDL stores cholesterol in the blood stream
  • HDL regulates LDL storage and promotes excretion
96
Q

Risk Factors for Coronary Heart Disease

A
  • Age > 45 for men, 55 for women
  • Family history
  • Cigarette smoking
  • Hypertension
  • Diabetes
  • High cholesterol (esp LDL)
97
Q

CHD and Cholesterol

A

-Risk for death due to CHD is 4x higher at a total cholesterol level of 300 mg/dL (7.2 mmol/L) than at 150 mg/dL (3.6 mmol/L)

98
Q

Classification of Cholesterol Levels

A
  • LDL: 4.1-4.9 mmol/L is HIGH

- Total Cholesterol: >6.2 mmol/L is HIGH

99
Q

Target Cholesterol Levels and CHD

A

LDL Goals

-CHD and CHD 10 year risk > 20% –>

100
Q

Measurement of Cholesterol

A

Enzymatic Assay

  1. Hydrolyse cholesterol esters with cholesteryl esterase to release free cholesterol
  2. Cholesterol –cholesterol oxidase–> cholestenone + H2O2
  3. H2O2 + dye –peroxidase–> colour (500 nm)
101
Q

Measurement of Triglycerides

A
  • Enzymatic Assay
  • Glycerol is part of the chain, but there is a lot of glycerol present in the blood, which causes an overestimation of the triglycerides in the body by 10-20 mg/dL
102
Q

Measurement of LDL and HDL

A

-Plasma same is ultracentrifuged to separate VLDL, LDL and HDL
-Total cholesterol, TG and HDL are measured
-VLDL is estimated (TG/5) and LDL is then calculated as:
LDL = TC - HDL - TG/5

103
Q

Arterial Blood Gases

A
  1. Oxygen
    - Oxygen saturation (SO2)
    - Fraction oxyhemoglobin (FO2Hb)
    - Partial pressure of oxygen in plasma (pO2)
    - Pulse oximetry (SpO2)
  2. Carbon Dioxide
    - Expressed as partial pressure CO2 in plasma (pCO2)
104
Q

Oxygen Saturation

A
  • SO2 is the fraction of O2 bound to hemoglobin compared to total O2 binding capacity of Hb in blood
  • Oxygenated Hb (O2Hb) and deoxygenated Hb (HHb) are measured based on different spectrophotometric absorbance
  • Fraction of oxyhemoglobin (FO2Hb) is also measured

SO2 = [O2Hb]/([O2Hb]+[HHb]) x 100%

  • Normal levels should be 95-100%
  • Below 90% is hypoxic
  • Below 80% can lead to compromised organ function
105
Q

Pulse Oximetry

A
  • Measures absorbance of oxyhemoglobin and hemoglobin and calculates ratio
  • Based on differential absorbance of red (660 nm) and infrared (910 nm) light by O2Hb and HHb
  • Estimates oxygen saturation (SpO2)
106
Q

pO2 and pCO2

A
  • At sea level, barometric pressure is 760 mmHg
  • pO2 = 760 x 20.93% = 159 mmHg
  • pCO2 = 760 x 0.03% = 0.23 mmHg

-In blood and tissues, there are changes in pO2 and pCO2 in the blood from arterial blood in the lungs to venous blood returning from the tissues
+pO2: Arterial > Venous
+pCO2: Venous > Arterial
-Most oxygen in the blood is carried by Hb (98%)
+pO2 and pCO2 only reflect dissolved O2 and CO2 in the blood
-pO2 gives idea of how effective the lungs are at pulling oxygen from the atmosphere to blood

107
Q

Measurement of pO2

A

Clarke Electrode

  • Oxygen diffuses across a membrane into an electrolyte solution and is then reduced at a platinum cathode
  • Type of galvanic cell –> results in a CURRENT flowing which can be used to quantify amount of O2

O2 + 4 e- + 2 H2O –> 4 OH-

108
Q

Measurement of pCO2

A

Severinghaus Electrode

  • CO2 diffuses across a membrane and forms carbonic acid, which then dissociates to H+ and HCO3- –> reduced pH
  • Based on reduction in pH, CO2 can be determined
109
Q

Blood Gas Analyzer

A

-Includes all 3 electrodes to measure pH, pO2 and pCO2

110
Q

Iron in the Body

A
  1. Hemoglobin
    - O2, CO2 and iron transport
  2. Myoglobin
    - Hb in muscle
  3. Transferrin
    - Iron transfer
  4. Ferritin
    - Iron storage and release in controlled fashion
  5. Cytochromes and other enzymes
    - Iron binding and various other functions
111
Q

Laboratory Iron Markers

A

Important Measurements

  1. Serum Fe
  2. Transferrin
  3. Ferritin
  4. %Fe Saturation
  5. TIBC (total iron binding capacity; measure of how well transferrin is working)
112
Q

Measurement of Serum Fe

A

Fe-Proteins –[H+]–> Fe3+ –ascorbic acid–> Fe2+ + Ferrozine –> absorbance at 562 nm

113
Q

Changes in Iron Markers in Disease

A
  1. Iron deficiency
    - Decrease in serum iron, %saturation and ferritin
    - Increase in transferrin
  2. Chronic anemia
    - Decrease in serum iron and %saturation
    - Decrease or same transferrin
    - Increase or same ferritin
  3. Iron Poisoning
    - Decrease in transferrin
    - Increase in serum iron, %saturation and ferritin

NOTE: transferrin and ferritin are measured by ELISA

Second Year Things (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions